GLASGOW – The registry-based study showed that more than 70% of patients who presented with thrombotic thrombocytopenic purpura had neurological...
NEW ORLEANS – Twelve-month outcomes of TREAT study show no safety or efficacy differences.
GLASGOW – This research could guide the development of treatment strategies for hundreds of thousands of patients each year, particularly children...
NEW ORLEANS – Ticagrelor’s antiplatelet effect was squelched within 5 minutes.
From the Journals
NEW ORLEANS – Dropping aspirin but keeping anticoagulation with apixaban and antiplatelet clopidogrel was effective and associated with less...
HONOLULU – The drug establishes good or excellent hemostasis in 82% of patients with acute major bleeding associated...
Many questions remain following the FDA’s approval of caplacizumab, specifically, which patients should receive it. The high cost of the drug is...
SEATTLE – Two studies detail the risk factors of first-time venous thromboembolism and heightened incidence of repeat VTE in patients with HIV.